XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of unmet clinical needs. XTL is focused on late stage clinical development of its two core assets: hCDR1 for the treatment of SLE/lupus and rHuEPO for “no-option” multiple myeloma patients. rHuEPO has demonstrated a significant survival benefit for a number of end-stage multiple myeloma patients and results have been published in medical journals. XTL owns a use patent and has obtained orphan drug designation for this application of the drug in the United States. For more information, visit the company’s website at www.xtlbio.com